Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 5/20 | 0.70 |
| ▸ | FABP3 | P05413 | 4/20 | 0.70 |
| ▸ | FABP5 | Q01469 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 8/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11545050 | 0.93 | FABP4 (0.64) | FABP4FABP3FABP5ALDH1A1CYP2C9 | |
| SCHEMBL18285444 | 0.87 | FABP4 (0.68) | FABP4FABP3FABP5ALDH1A1CYP2C9 | |
| SCHEMBL10322427 | 0.86 | RXFP1 (0.55) | FABP4FABP3FABP5ALDH1A1CYP2C9 | |
| SCHEMBL6293298 | 0.85 | FABP3 (0.61) | FABP4FABP3FABP5ALDH1A1GAA | |
| SCHEMBL18285435 | 0.82 | FABP3 (0.52) | FABP4FABP3FABP5ALDH1A1CYP2C9 | |
| SCHEMBL18285402 | 0.80 | FABP3 (0.50) | FABP4FABP3FABP5ALDH1A1GAA | |
| SCHEMBL27638732 | 0.80 | POLB (0.56) | FABP4FABP3FABP5ALDH1A1CYP2C9 | |
| SCHEMBL537930 | 0.79 | FABP4 (0.46) | FABP4FABP3FABP5ALDH1A1CYP2C9 | |
| SCHEMBL3807965 | 0.77 | FABP3 (0.47) | FABP4FABP3FABP5ALDH1A1CYP2C9 | |
| SCHEMBL9869545 | 0.77 | FABP4 (0.49) | FABP4FABP3FABP5ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427582-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | UWM RESEARCH FOUNDATION, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210047322-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-18 | — | — | US | disclosed |
| US-10865203-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | UWM RESEARCH FOUNDATION, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3325479-B1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | UWM RES FOUNDATION INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3325479-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAa RECEPTORS ANS THEIR METHODS OF USE | UWM Research Foundation, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20180134698-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-05-17 | — | — | US | disclosed |
| WO-2016196961-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS ANS THEIR METHODS OF USE | UWM RESEARCH FOUNDATION, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-8889706-B2 | Soluble mTOR complexes and modulators thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2350053-B1 | Modulators of MTOR Complexes | WHITEHEAD BIOMEDICAL INST (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2350053-A2 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | Whitehead Institute For Biomedical Research (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010044885-A2 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047322-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | GABRA6, HTR6, GABRD | FABP4 1209/4885FABP3 537/4885FABP5 611/4885 |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | FABP4 2231/4885FABP3 2903/4885FABP5 2100/4885 |
| US-20180134698-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | GABRA6, HTR6, GABRD | FABP4 924/4885FABP3 427/4885FABP5 495/4885 |
| US-11427582-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | GABRA6, HTR6, GABRD | FABP4 1209/4885FABP3 537/4885FABP5 611/4885 |
| US-10865203-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | GABRA6, HTR6, GABRD | FABP4 924/4885FABP3 427/4885FABP5 495/4885 |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | FABP4 2231/4885FABP3 2903/4885FABP5 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.